Off-Label Use in Rare Diseases: Myasthenia Gravis, Lambert-Eaton Myasthenic Syndrome and Congenital Myasthenic Syndromes
Neurology International Open · 01.04.2018 · 2 (02) · E118-E123
DOI: 10.1055/s-0044-100184 ↗Kurz gefasst
Fachartikel in der Zeitschrift Neurology International Open, erschienen am 01.04.2018. Verfasst von Rudolf Janzen. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
The off-label use of licensed drugs is widespread, and the risk of adverse events is elevated, especially if the scientific evidence is low. The treatment of rare diseases (
Zitieren
APA
Janzen, R. (2018). Off-Label Use in Rare Diseases: Myasthenia Gravis, Lambert-Eaton Myasthenic Syndrome and Congenital Myasthenic Syndromes. Neurology International Open, 2(02), E118-E123. https://doi.org/10.1055/s-0044-100184
Vancouver
Janzen R. Off-Label Use in Rare Diseases: Myasthenia Gravis, Lambert-Eaton Myasthenic Syndrome and Congenital Myasthenic Syndromes. Neurology International Open. 2018;2(02):E118-E123. doi:10.1055/s-0044-100184
BibTeX
@article{Janzen2018,
author = {Janzen, Rudolf},
title = {Off-Label Use in Rare Diseases: Myasthenia Gravis, Lambert-Eaton Myasthenic Syndrome and Congenital Myasthenic Syndromes},
journal = {Neurology International Open},
year = {2018},
volume = {2},
number = {02},
pages = {E118--E123},
doi = {10.1055/s-0044-100184}
}
EUVIMED